Central Nervous System Drugs Market Global Report 2017
出 版 商：TBRC
出版日期：2017/07/17
頁 數：125頁
文件格式：PDF
價 格：
USD 4,000 (Single-User License)
USD 6,000 (Multi-User License)
USD 8,000 (Global-User License)
USD 4,000 (Hard copy)
USD 6,000 (Multi-User License)
USD 8,000 (Global-User License)
USD 4,000 (Hard copy)
Regenerative therapies for the treatment of central nervous system diseases is one of the emerging trend in the global central nervous system drugs market. These therapies will help in the healing process by replacing or regenerating human cells, tissues, and organs. The major regenerative therapies include transplantation by embryonic stem cells, usage of matrix such as fibrin, collagen, and hyaluronic acid.
The Central Nervous System Drugs Market Global Report provides strategists, marketers and senior management with the critical information they need to assess the global central nervous system drugs sector.
Reasons to Purchase
‧ Outperform competitors using accurate up to date demand-side dynamics information.
‧ Identify growth segments for investment.
‧ Facilitate decision making on the basis of historic and forecast data and the drivers and restraints on the market.
‧ Create regional and country strategies on the basis of local data and analysis.
‧ Stay abreast of the latest customer and market research findings
‧ Benchmark performance against key competitors.
‧ Develop strategies based on likely future developments.
‧ Utilize the relationships between key data sets for superior strategizing.
‧ Suitable for supporting your internal and external presentations with reliable high quality data and analysis
‧ Gain a global perspective on the development of the market.
‧ Report will be updated with the latest data and delivered to you within 3-5 working days of order.
Description:
Where is the largest and fastest growing market for the central nervous system drugs? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The central nervous system drugs market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography. It places the market within the context of the wider pharmaceutical drugs market, and compares it with other markets.
‧ The market characteristics section of the report defines and explains the market.
‧ The market size section gives the market size ($b) covering both the historic growth of the market and forecasting the future. Drivers and restraints looks at the external factors supporting and controlling the growth of the market.
‧ Market segmentations break down market into sub markets.
‧ The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers all the regions, key developed countries and major emerging markets. It draws comparisons with country populations and economies to understand the importance of the market by country and how this is changing.
‧ Competitive landscape gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
‧ The trends and strategies section highlights the likely future developments in the market and suggests approaches companies can take to exploit this.
‧ The central nervous system drugs market section of the report gives context. It compares the central nervous system drugs market with other segments of the pharmaceutical drugs market by size and growth, historic and forecast. It analyses Expenditure Per Capita, The Central Nervous System Drugs Indicators Comparison.
‧ The industry metrics section looks at critical drivers including patient numbers (epidemiology) hospital beds and specialist physicians while the macro-economic section looks at the market in relation to the overall economy.
Scope
Markets Covered: Analgesics, Anti-Parkinson Drugs, Anaesthetics, Anti-Epileptics, Other CNS Drugs
Companies Mentioned: Pfizer Inc., Biogen Idec, Novartis AG, Otsuka, and Teva Pharmaceuticals
Countries: Brazil, China, France, Germany, India, Italy, Japan, Spain, Russia, UK, USA and Australia.
Regions: Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East And Africa
Time series: Five years historic and forecast.
Data: Ratios of market size and growth to related markets, GDP, Expenditure Per Capita, The Central Nervous System Drugs Indicators Comparison.
Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
The Central Nervous System Drugs Market Global Report provides strategists, marketers and senior management with the critical information they need to assess the global central nervous system drugs sector.
Reasons to Purchase
‧ Outperform competitors using accurate up to date demand-side dynamics information.
‧ Identify growth segments for investment.
‧ Facilitate decision making on the basis of historic and forecast data and the drivers and restraints on the market.
‧ Create regional and country strategies on the basis of local data and analysis.
‧ Stay abreast of the latest customer and market research findings
‧ Benchmark performance against key competitors.
‧ Develop strategies based on likely future developments.
‧ Utilize the relationships between key data sets for superior strategizing.
‧ Suitable for supporting your internal and external presentations with reliable high quality data and analysis
‧ Gain a global perspective on the development of the market.
‧ Report will be updated with the latest data and delivered to you within 3-5 working days of order.
Description:
Where is the largest and fastest growing market for the central nervous system drugs? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The central nervous system drugs market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography. It places the market within the context of the wider pharmaceutical drugs market, and compares it with other markets.
‧ The market characteristics section of the report defines and explains the market.
‧ The market size section gives the market size ($b) covering both the historic growth of the market and forecasting the future. Drivers and restraints looks at the external factors supporting and controlling the growth of the market.
‧ Market segmentations break down market into sub markets.
‧ The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers all the regions, key developed countries and major emerging markets. It draws comparisons with country populations and economies to understand the importance of the market by country and how this is changing.
‧ Competitive landscape gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
‧ The trends and strategies section highlights the likely future developments in the market and suggests approaches companies can take to exploit this.
‧ The central nervous system drugs market section of the report gives context. It compares the central nervous system drugs market with other segments of the pharmaceutical drugs market by size and growth, historic and forecast. It analyses Expenditure Per Capita, The Central Nervous System Drugs Indicators Comparison.
‧ The industry metrics section looks at critical drivers including patient numbers (epidemiology) hospital beds and specialist physicians while the macro-economic section looks at the market in relation to the overall economy.
Scope
Markets Covered: Analgesics, Anti-Parkinson Drugs, Anaesthetics, Anti-Epileptics, Other CNS Drugs
Companies Mentioned: Pfizer Inc., Biogen Idec, Novartis AG, Otsuka, and Teva Pharmaceuticals
Countries: Brazil, China, France, Germany, India, Italy, Japan, Spain, Russia, UK, USA and Australia.
Regions: Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East And Africa
Time series: Five years historic and forecast.
Data: Ratios of market size and growth to related markets, GDP, Expenditure Per Capita, The Central Nervous System Drugs Indicators Comparison.
Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
1. Central Nervous System Drugs Market Characteristics;
2. Central Nervous System Drugs Market Size And Growth;
2.1. Historic Market Growth; 2.1.1. Drivers Of The Market; 2.1.2. Restraints On The Market; 2.2. Forecast Market Growth; 2.2.1. Drivers Of The Market; 2.2.2. Restraints On The Market;
3. Pestle Analysis;
3.1. Political; 3.2. Economic; 3.3. Social; 3.4. Technological; 3.5. Legal; 3.6. Environmental;
4. Central Nervous System Drugs Market Customer Information;
5. Central Nervous System Drugs Market Segmentation;
5.1. Global Central Nervous System Drugs Market, 2016, By Segment; Analgesics; Anti-Parkinson Drugs; Anaesthetics; Anti-Epileptics; Other CNS Drugs; 5.2. Global Central Nervous System Drugs Market, 2012 - 2020, Historic And Forecast, By Segment; 5.3 Global Central Nervous System Drugs Market Trends And Strategies;
6. Central Nervous System Drugs Market Regional And Country Analysis;
6.1. Global Central Nervous System Drugs Market, 2016, By Region; 6.2. Global Central Nervous System Drugs Market, 2012 - 2020, Historic And Forecast, By Region; 6.3. Central Nervous System Drugs Market, 2016, By Country; 6.4. Central Nervous System Drugs Market, 2012 - 2020, Historic And Forecast, By Country; 6.5. Global Pharmaceutical Market Segments, 2016, By Region; 6.6 Global Pharmaceutical Drugs Market Segments, 2016, By Region; 6.7 Global Pharmaceutical Market Segments, 2016, By Country; 6.8 Global Pharmaceutical Drugs Market Segments, 2016, By Country;
7. Global Central Nervous System Drugs Market Comparison With Macro Economic Factors;
7.1. Central Nervous System Drugs Market Size, Percentage Of GDP, Global; 7.2. Per Capita Average Central Nervous System Drugs Expenditure, Global;
8. Central Nervous System Drugs Market Comparison With Macro Economic Factors Across Countries;
8.1. Central Nervous System Drugs Market Size, Percentage Of GDP, By Country; 8.2. Per Capita Average Central Nervous System Drugs Expenditure, By Country;
9. Central Nervous System Drugs Market Comparison With Industry Metrics;
9.1. Global Number Of Pharmacists, 2016, By Country; 9.2. Global Central Nervous System Drugs Market Revenue Versus Number Of Pharmacists, 2016, By Country; 9.3. Global Number Of Pharma Enterprises, 2016, By Country; 9.4. Global Central Nervous System Drugs Market Revenue Versus Number Of Pharma Enterprises, 2016, By Country; 9.5. Global Average Spending On R&D/Product Development, 2016, By Country; 9.6. Global Central Nervous System Drugs Market Revenue Versus Average Spending On R&D/Product Development, 2016, By Country; 9.7. Global Generic & Branded Sales Proportion By Country (Value), 2016, By Country; 9.8. Global Central Nervous System Drugs Market Revenue Versus Generic & Branded Sales Proportion By Country (Value), 2016, By Country; 9.9. Prevalent Cases Of Parkinsons Disease, 2014, By Country; 9.10. Global Number Of Psychiatrists, 2016, By Country; 9.11. Global Central Nervous System Drugs Market Revenue Versus Number Of Psychiatrists, 2016, By Country; 9.12. Global Number Of General Practitioners 2016, By Country; 9.13. Global Central Nervous System Drugs Market Revenue Versus Number Of General Practitioners, 2016, By Country;
10. Asia-Pacific Central Nervous System Drugs Market;
10.1.1. Asia-Pacific Central Nervous System Drugs Market Overview; 10.1.2. Asia-Pacific Central Nervous System Drugs Historic Market, 2012 - 2016; 10.1.3. Asia-Pacific Central Nervous System Drugs Forecast Market, 2016 - 2020; 10.1.4. Asia-Pacific Central Nervous System Drugs Market, 2016, By Segment; Analgesics; Anti-Parkinson Drugs; Anaesthetics; Anti-Epileptics; Other CNS Drugs; 10.2. Asia-Pacific Central Nervous System Drugs Market: Country Analysis; 10.3. China Central Nervous System Drugs Market; 10.3.1. China Central Nervous System Drugs Market Overview; 10.3.2. China Central Nervous System Drugs Historic Market, 2012 - 2016; 10.3.3. China Central Nervous System Drugs Forecast Market, 2016 - 2020; 10.3.4. China Central Nervous System Drugs Market, 2016, By Segment; Analgesics; Anti-Parkinson Drugs; Anaesthetics; Anti-Epileptics; Other CNS Drugs; 10.3.5. China Central Nervous System Drugs Percentage Of GDP, 2012 - 2020; 10.3.6. China Per Capita Average Central Nervous System Drugs Expenditure, 2012 - 2020; 10.4. India Central Nervous System Drugs Market; 10.4.1. India Central Nervous System Drugs Market Overview; 10.4.2. India Central Nervous System Drugs Historic Market, 2012 - 2016; 10.4.3. India Central Nervous System Drugs Forecast Market, 2016 - 2020; 10.4.4. India Central Nervous System Drugs Market, 2016, By Segment; Analgesics; Anti-Parkinson Drugs; Anaesthetics; Anti-Epileptics; Other CNS Drugs; 10.4.5. India Central Nervous System Drugs Percentage Of GDP, 2012 - 2020; 10.4.6. India Per Capita Average Central Nervous System Drugs Expenditure, 2012 - 2020; 10.5. Japan Central Nervous System Drugs Market; 10.5.1. Japan Central Nervous System Drugs Market Overview; 10.5.2. Japan Central Nervous System Drugs Historic Market, 2012 - 2016; 10.5.3. Japan Central Nervous System Drugs Forecast Market, 2016 - 2020; 10.5.4. Japan Central Nervous System Drugs Market, 2016, By Segment; Analgesics; Anti-Parkinson Drugs; Anaesthetics; Anti-Epileptics; Other CNS Drugs; 10.5.5. Japan Central Nervous System Drugs Percentage Of GDP, 2012 - 2020; 10.5.6. Japan Per Capita Average Central Nervous System Drugs Expenditure, 2012 - 2020; 10.6. Australia Central Nervous System Drugs Market; 10.6.1. Australia Central Nervous System Drugs Historic Market, 2012 - 2016; 10.6.2. Australia Central Nervous System Drugs Forecast Market, 2016 - 2020; 10.6.3. Australia Central Nervous System Drugs Market, 2016, By Segment; Analgesics; Anti-Parkinson Drugs; Anaesthetics; Anti-Epileptics; Other CNS Drugs; 10.6.4. Australia Central Nervous System Drugs Percentage Of GDP, 2012 - 2020; 10.6.5. Australia Per Capita Average Central Nervous System Drugs Expenditure, 2012 - 2020;
11. Western Europe Central Nervous System Drugs Market;
11.1.1. Western Europe Central Nervous System Drugs Market Overview; 11.1.2. Western Europe Central Nervous System Drugs Historic Market, 2012 - 2016; 11.1.3. Western Europe Central Nervous System Drugs Forecast Market, 2016 - 2020; 11.1.4. Western Europe Central Nervous System Drugs Market, 2016, By Segment; Analgesics; Anti-Parkinson Drugs; Anaesthetics; Anti-Epileptics; Other CNS Drugs; 11.2. Western Europe Central Nervous System Drugs Market: Country Analysis; 11.3. UK Central Nervous System Drugs Market; 11.3.1. UK Central Nervous System Drugs Market Overview; 11.3.2. UK Central Nervous System Drugs Historic Market, 2012 - 2016; 11.3.3. UK Central Nervous System Drugs Forecast Market, 2016 - 2020; 11.3.4. UK Central Nervous System Drugs Market, 2016, By Segment; Analgesics; Anti-Parkinson Drugs; Anaesthetics; Anti-Epileptics; Other CNS Drugs; 11.3.5. UK Central Nervous System Drugs Percentage Of GDP, 2012 - 2020; 11.3.6. UK Per Capita Average Central Nervous System Drugs Expenditure, 2012 - 2020; 11.4. Germany Central Nervous System Drugs Market; 11.4.1. Germany Central Nervous System Drugs Historic Market, 2012 - 2016; 11.4.2. Germany Central Nervous System Drugs Forecast Market, 2016 - 2020; 11.4.3. Germany Central Nervous System Drugs Market, 2016, By Segment; Analgesics; Anti-Parkinson Drugs; Anaesthetics; Anti-Epileptics; Other CNS Drugs; 11.4.4 Germany Central Nervous System Drugs Percentage Of GDP, 2012 - 2020; 11.4.5 Germany Per Capita Average Central Nervous System Drugs Expenditure, 2012 - 2020; 11.5 France Central Nervous System Drugs Market; 11.5.1 France Central Nervous System Drugs Historic Market, 2012 - 2016; 11.5.2 France Central Nervous System Drugs Forecast Market, 2016 - 2020; 11.5.3 France Central Nervous System Drugs Market, 2016, By Segment; Analgesics; Anti-Parkinson Drugs; Anaesthetics; Anti-Epileptics; Other CNS Drugs; 11.5.4 France Central Nervous System Drugs Percentage Of GDP, 2012 - 2020; 11.5.5 France Per Capita Average Central Nervous System Drugs Expenditure, 2012 - 2020; 11.6. Italy Central Nervous System Drugs Market; 11.6.1. Italy Central Nervous System Drugs Historic Market, 2012 - 2016; 11.6.2. Italy Central Nervous System Drugs Forecast Market, 2016 - 2020; 11.6.3. Italy Central Nervous System Drugs Market, 2016, By Segment; Analgesics; Anti-Parkinson Drugs; Anaesthetics; Anti-Epileptics; Other CNS Drugs; 11.6.4. Italy Central Nervous System Drugs Percentage Of GDP, 2012 - 2020; 11.6.5. Italy Per Capita Average Central Nervous System Drugs Expenditure, 2012 - 2020; 11.7. Spain Central Nervous System Drugs Market; 11.7.1. Spain Central Nervous System Drugs Historic Market, 2012 - 2016; 11.7.2. Spain Central Nervous System Drugs Forecast Market, 2016 - 2020; 11.7.3. Spain Central Nervous System Drugs Market, 2016, By Segment; Analgesics; Anti-Parkinson Drugs; Anaesthetics; Anti-Epileptics; Other CNS Drugs; 11.7.4. Spain Central Nervous System Drugs Percentage Of GDP, 2012 - 2020; 11.7.5. Spain Per Capita Average Central Nervous System Drugs Expenditure, 2012 - 2020; 12. Eastern Europe Central Nervous System Drugs Market;
12. Eastern Europe Central Nervous System Drugs Market;
12.1.1. Eastern Europe Central Nervous System Drugs Market Overview; 12.1.2. Eastern Europe Central Nervous System Drugs Historic Market, 2012 - 2016; 12.1.3. Eastern Europe Central Nervous System Drugs Forecast Market, 2016 - 2020; 12.1.4 Eastern Europe Central Nervous System Drugs Market, 2016, By Segment; Analgesics; Anti-Parkinson Drugs; Anaesthetics; Anti-Epileptics; Other CNS Drugs; 12.2. Eastern Europe Central Nervous System Drugs Market: Country Analysis; 12.3. Russia Central Nervous System Drugs Market; 12.3.1. Russia Central Nervous System Drugs Historic Market, 2012 - 2016; 12.3.2. Russia Central Nervous System Drugs Forecast Market, 2016 - 2020; 12.3.3. Russia Central Nervous System Drugs Market, 2016, By Segment; Analgesics; Anti-Parkinson Drugs; Anaesthetics; Anti-Epileptics; Other CNS Drugs; 12.3.4. Russia Central Nervous System Drugs Percentage Of GDP, 2012 - 2020; 12.3.5. Russia Per Capita Average Central Nervous System Drugs Expenditure, 2012 - 2020;
13. North America Central Nervous System Drugs Market;
13.1.1. North America Central Nervous System Drugs Market Overview; 13.1.2. North America Central Nervous System Drugs Historic Market, 2012 - 2016; 13.1.3. North America Central Nervous System Drugs Forecast Market, 2016 - 2020; 13.1.4. North America Central Nervous System Drugs Market, 2016, By Segment; Analgesics; Anti-Parkinson Drugs; Anaesthetics; Anti-Epileptics; Other CNS Drugs; 13.2. North America Central Nervous System Drugs Market: Country Analysis; 13.3. USA Central Nervous System Drugs Market; 13.3.1. USA Central Nervous System Drugs Historic Market, 2012 - 2016; 13.3.2. USA Central Nervous System Drugs Forecast Market, 2016 - 2020; 13.3.3 USA Central Nervous System Drugs Market, 2016, By Segment; Analgesics; Anti-Parkinson Drugs; Anaesthetics; Anti-Epileptics; Other CNS Drugs; 13.3.4. USA Central Nervous System Drugs Percentage Of GDP, 2012 - 2020; 13.3.5. USA Per Capita Average Central Nervous System Drugs Expenditure, 2012 - 2020;
14. South America Central Nervous System Drugs Market;
14.1.1. South America Central Nervous System Drugs Market Overview; 14.1.2. South America Central Nervous System Drugs Historic Market, 2012 - 2016; 14.1.3. South America Central Nervous System Drugs Forecast Market, 2016 - 2020; 14.1.4. South America Central Nervous System Drugs Market, 2016, By Segment; Analgesics; Anti-Parkinson Drugs; Anaesthetics; Anti-Epileptics; Other CNS Drugs; 14.2. South America Central Nervous System Drugs Market: Country Analysis; 14.3. Brazil Central Nervous System Drugs Market; 14.3.1. Brazil Central Nervous System Drugs Historic Market, 2012 - 2016; 14.3.2. Brazil Central Nervous System Drugs Forecast Market, 2016 - 2020; 14.3.3. Brazil Central Nervous System Drugs Market, 2016, By Segment; Analgesics; Anti-Parkinson Drugs; Anaesthetics; Anti-Epileptics; Other CNS Drugs; 14.3.4. Brazil Central Nervous System Drugs Percentage Of GDP, 2012 - 2020; 14.3.5. Brazil Per Capita Average Central Nervous System Drugs Expenditure, 2012 - 2020;
15. Middle East Central Nervous System Drugs Market;
15.1.1. Middle East Central Nervous System Drugs Market Overview; 15.1.2. Middle East Central Nervous System Drugs Historic Market, 2012 - 2016; 15.1.3. Middle East Central Nervous System Drugs Forecast Market, 2016 - 2020; 15.1.4. Middle East Central Nervous System Drugs Market, 2016, By Segment; Analgesics; Anti-Parkinson Drugs; Anaesthetics; Anti-Epileptics; Other CNS Drugs;
16. Africa Central Nervous System Drugs Market;
16.1.1. Africa Central Nervous System Drugs Market Overview; 16.1.2. Africa Central Nervous System Drugs Historic Market, 2012 - 2016; 16.1.3. Africa Central Nervous System Drugs Forecast Market, 2016 - 2020; 16.1.4. Africa Central Nervous System Drugs Market, 2016, By Segment; Analgesics; Anti-Parkinson Drugs; Anaesthetics; Anti-Epileptics;
17. Central Nervous System Drugs Market Competitive Landscape;
17.1. Company Profiles; 17.2. Pfizer Inc.; 17.2.1. Overview; 17.2.2. Products And Services; 17.2.3. Strategy; 17.2.4. Financial Performance; 17.3. Biogen Idec; 17.3.1. Overview; 17.3.2. Products And Services; 17.3.3. Strategy; 17.3.4. Financial Performance; 17.4. Novartis Ag; 17.4.1. Overview; 17.4.2. Products And Services; 17.4.3. Strategy; 17.4.4. Financial Performance; 17.5. Otsuka; 17.5.1. Overview; 17.5.2. Products And Services; 17.5.3. Strategy; 17.5.4. Financial Performance; 17.6. Teva Pharmaceuticals; 17.6.1. Overview; 17.6.2. Products And Services; 17.6.3. Strategy; 17.6.4. Financial Performance;
18. Key Mergers And Acquisitions In The Central Nervous System Drugs Market;
19. Market Background: Pharmaceutical Drugs Market;
19.1.1. Pharmaceutical Drugs Market Characteristics; 19.1.2. Pharmaceutical Drugs Market Historic Growth; 19.1.2.1. Drivers Of The Market; 19.1.2.2. Restraints Of The Market; 19.1.3. Pharmaceutical Drugs Market Forecast Growth; 19.1.3.1. Drivers Of The Market; 19.1.3.2. Restraints Of The Market; 19.1.4. Pharmaceutical Drugs Trends And Strategies; 19.2. Pharmaceutical Drugs Market Regional And Country Analysis; 19.2.1. Global Pharmaceutical Drugs Market, 2016, By Region; 19.2.2. Global Pharmaceutical Drugs Market, 2012 - 2020, Historic And Forecast, By Region; 19.2.3. Pharmaceutical Drugs Market, 2016, By Country; 19.2.4. Pharmaceutical Drugs Market, 2012 - 2020, Historic And Forecast, By Country; 19.2.5. Global Pharmaceutical Drugs Market, Growth And Market Share Comparison, By Segment; 19.2.6. Global Pharmaceutical Drugs Market, Growth And Market Share Comparison, By Country And Segment; 19.3. Global Pharmaceutical Drugs Market Comparison With Macro Economic Factors; 19.3.1. Pharmaceutical Drugs Market Size, Percentage Of GDP, Global; 19.3.2. Per Capita Average Pharmaceutical Drugs Expenditure, Global; 19.4. Pharmaceutical Drugs Market Comparison With Macro Economic Factors Across Countries; 19.4.1. Pharmaceutical Drugs Market Size, Percentage Of GDP, By Country; 19.4.2. Per Capita Average Pharmaceutical Drugs Expenditure, By Country; 19.5. Key Mergers And Acquisitions In The Pharmaceutical Drugs Market;
20. Pharmaceuticals Industry Financial Margins;
21. Appendix;
21.1. NAICS Definitions Of Industry Covered In This Report; 21.2. Abbreviations; 21.3. Currencies; 21.4. Research Inquiries; 21.5. The Business Research Company; 21.6. Copyright And Disclaimer
2. Central Nervous System Drugs Market Size And Growth;
2.1. Historic Market Growth; 2.1.1. Drivers Of The Market; 2.1.2. Restraints On The Market; 2.2. Forecast Market Growth; 2.2.1. Drivers Of The Market; 2.2.2. Restraints On The Market;
3. Pestle Analysis;
3.1. Political; 3.2. Economic; 3.3. Social; 3.4. Technological; 3.5. Legal; 3.6. Environmental;
4. Central Nervous System Drugs Market Customer Information;
5. Central Nervous System Drugs Market Segmentation;
5.1. Global Central Nervous System Drugs Market, 2016, By Segment; Analgesics; Anti-Parkinson Drugs; Anaesthetics; Anti-Epileptics; Other CNS Drugs; 5.2. Global Central Nervous System Drugs Market, 2012 - 2020, Historic And Forecast, By Segment; 5.3 Global Central Nervous System Drugs Market Trends And Strategies;
6. Central Nervous System Drugs Market Regional And Country Analysis;
6.1. Global Central Nervous System Drugs Market, 2016, By Region; 6.2. Global Central Nervous System Drugs Market, 2012 - 2020, Historic And Forecast, By Region; 6.3. Central Nervous System Drugs Market, 2016, By Country; 6.4. Central Nervous System Drugs Market, 2012 - 2020, Historic And Forecast, By Country; 6.5. Global Pharmaceutical Market Segments, 2016, By Region; 6.6 Global Pharmaceutical Drugs Market Segments, 2016, By Region; 6.7 Global Pharmaceutical Market Segments, 2016, By Country; 6.8 Global Pharmaceutical Drugs Market Segments, 2016, By Country;
7. Global Central Nervous System Drugs Market Comparison With Macro Economic Factors;
7.1. Central Nervous System Drugs Market Size, Percentage Of GDP, Global; 7.2. Per Capita Average Central Nervous System Drugs Expenditure, Global;
8. Central Nervous System Drugs Market Comparison With Macro Economic Factors Across Countries;
8.1. Central Nervous System Drugs Market Size, Percentage Of GDP, By Country; 8.2. Per Capita Average Central Nervous System Drugs Expenditure, By Country;
9. Central Nervous System Drugs Market Comparison With Industry Metrics;
9.1. Global Number Of Pharmacists, 2016, By Country; 9.2. Global Central Nervous System Drugs Market Revenue Versus Number Of Pharmacists, 2016, By Country; 9.3. Global Number Of Pharma Enterprises, 2016, By Country; 9.4. Global Central Nervous System Drugs Market Revenue Versus Number Of Pharma Enterprises, 2016, By Country; 9.5. Global Average Spending On R&D/Product Development, 2016, By Country; 9.6. Global Central Nervous System Drugs Market Revenue Versus Average Spending On R&D/Product Development, 2016, By Country; 9.7. Global Generic & Branded Sales Proportion By Country (Value), 2016, By Country; 9.8. Global Central Nervous System Drugs Market Revenue Versus Generic & Branded Sales Proportion By Country (Value), 2016, By Country; 9.9. Prevalent Cases Of Parkinsons Disease, 2014, By Country; 9.10. Global Number Of Psychiatrists, 2016, By Country; 9.11. Global Central Nervous System Drugs Market Revenue Versus Number Of Psychiatrists, 2016, By Country; 9.12. Global Number Of General Practitioners 2016, By Country; 9.13. Global Central Nervous System Drugs Market Revenue Versus Number Of General Practitioners, 2016, By Country;
10. Asia-Pacific Central Nervous System Drugs Market;
10.1.1. Asia-Pacific Central Nervous System Drugs Market Overview; 10.1.2. Asia-Pacific Central Nervous System Drugs Historic Market, 2012 - 2016; 10.1.3. Asia-Pacific Central Nervous System Drugs Forecast Market, 2016 - 2020; 10.1.4. Asia-Pacific Central Nervous System Drugs Market, 2016, By Segment; Analgesics; Anti-Parkinson Drugs; Anaesthetics; Anti-Epileptics; Other CNS Drugs; 10.2. Asia-Pacific Central Nervous System Drugs Market: Country Analysis; 10.3. China Central Nervous System Drugs Market; 10.3.1. China Central Nervous System Drugs Market Overview; 10.3.2. China Central Nervous System Drugs Historic Market, 2012 - 2016; 10.3.3. China Central Nervous System Drugs Forecast Market, 2016 - 2020; 10.3.4. China Central Nervous System Drugs Market, 2016, By Segment; Analgesics; Anti-Parkinson Drugs; Anaesthetics; Anti-Epileptics; Other CNS Drugs; 10.3.5. China Central Nervous System Drugs Percentage Of GDP, 2012 - 2020; 10.3.6. China Per Capita Average Central Nervous System Drugs Expenditure, 2012 - 2020; 10.4. India Central Nervous System Drugs Market; 10.4.1. India Central Nervous System Drugs Market Overview; 10.4.2. India Central Nervous System Drugs Historic Market, 2012 - 2016; 10.4.3. India Central Nervous System Drugs Forecast Market, 2016 - 2020; 10.4.4. India Central Nervous System Drugs Market, 2016, By Segment; Analgesics; Anti-Parkinson Drugs; Anaesthetics; Anti-Epileptics; Other CNS Drugs; 10.4.5. India Central Nervous System Drugs Percentage Of GDP, 2012 - 2020; 10.4.6. India Per Capita Average Central Nervous System Drugs Expenditure, 2012 - 2020; 10.5. Japan Central Nervous System Drugs Market; 10.5.1. Japan Central Nervous System Drugs Market Overview; 10.5.2. Japan Central Nervous System Drugs Historic Market, 2012 - 2016; 10.5.3. Japan Central Nervous System Drugs Forecast Market, 2016 - 2020; 10.5.4. Japan Central Nervous System Drugs Market, 2016, By Segment; Analgesics; Anti-Parkinson Drugs; Anaesthetics; Anti-Epileptics; Other CNS Drugs; 10.5.5. Japan Central Nervous System Drugs Percentage Of GDP, 2012 - 2020; 10.5.6. Japan Per Capita Average Central Nervous System Drugs Expenditure, 2012 - 2020; 10.6. Australia Central Nervous System Drugs Market; 10.6.1. Australia Central Nervous System Drugs Historic Market, 2012 - 2016; 10.6.2. Australia Central Nervous System Drugs Forecast Market, 2016 - 2020; 10.6.3. Australia Central Nervous System Drugs Market, 2016, By Segment; Analgesics; Anti-Parkinson Drugs; Anaesthetics; Anti-Epileptics; Other CNS Drugs; 10.6.4. Australia Central Nervous System Drugs Percentage Of GDP, 2012 - 2020; 10.6.5. Australia Per Capita Average Central Nervous System Drugs Expenditure, 2012 - 2020;
11. Western Europe Central Nervous System Drugs Market;
11.1.1. Western Europe Central Nervous System Drugs Market Overview; 11.1.2. Western Europe Central Nervous System Drugs Historic Market, 2012 - 2016; 11.1.3. Western Europe Central Nervous System Drugs Forecast Market, 2016 - 2020; 11.1.4. Western Europe Central Nervous System Drugs Market, 2016, By Segment; Analgesics; Anti-Parkinson Drugs; Anaesthetics; Anti-Epileptics; Other CNS Drugs; 11.2. Western Europe Central Nervous System Drugs Market: Country Analysis; 11.3. UK Central Nervous System Drugs Market; 11.3.1. UK Central Nervous System Drugs Market Overview; 11.3.2. UK Central Nervous System Drugs Historic Market, 2012 - 2016; 11.3.3. UK Central Nervous System Drugs Forecast Market, 2016 - 2020; 11.3.4. UK Central Nervous System Drugs Market, 2016, By Segment; Analgesics; Anti-Parkinson Drugs; Anaesthetics; Anti-Epileptics; Other CNS Drugs; 11.3.5. UK Central Nervous System Drugs Percentage Of GDP, 2012 - 2020; 11.3.6. UK Per Capita Average Central Nervous System Drugs Expenditure, 2012 - 2020; 11.4. Germany Central Nervous System Drugs Market; 11.4.1. Germany Central Nervous System Drugs Historic Market, 2012 - 2016; 11.4.2. Germany Central Nervous System Drugs Forecast Market, 2016 - 2020; 11.4.3. Germany Central Nervous System Drugs Market, 2016, By Segment; Analgesics; Anti-Parkinson Drugs; Anaesthetics; Anti-Epileptics; Other CNS Drugs; 11.4.4 Germany Central Nervous System Drugs Percentage Of GDP, 2012 - 2020; 11.4.5 Germany Per Capita Average Central Nervous System Drugs Expenditure, 2012 - 2020; 11.5 France Central Nervous System Drugs Market; 11.5.1 France Central Nervous System Drugs Historic Market, 2012 - 2016; 11.5.2 France Central Nervous System Drugs Forecast Market, 2016 - 2020; 11.5.3 France Central Nervous System Drugs Market, 2016, By Segment; Analgesics; Anti-Parkinson Drugs; Anaesthetics; Anti-Epileptics; Other CNS Drugs; 11.5.4 France Central Nervous System Drugs Percentage Of GDP, 2012 - 2020; 11.5.5 France Per Capita Average Central Nervous System Drugs Expenditure, 2012 - 2020; 11.6. Italy Central Nervous System Drugs Market; 11.6.1. Italy Central Nervous System Drugs Historic Market, 2012 - 2016; 11.6.2. Italy Central Nervous System Drugs Forecast Market, 2016 - 2020; 11.6.3. Italy Central Nervous System Drugs Market, 2016, By Segment; Analgesics; Anti-Parkinson Drugs; Anaesthetics; Anti-Epileptics; Other CNS Drugs; 11.6.4. Italy Central Nervous System Drugs Percentage Of GDP, 2012 - 2020; 11.6.5. Italy Per Capita Average Central Nervous System Drugs Expenditure, 2012 - 2020; 11.7. Spain Central Nervous System Drugs Market; 11.7.1. Spain Central Nervous System Drugs Historic Market, 2012 - 2016; 11.7.2. Spain Central Nervous System Drugs Forecast Market, 2016 - 2020; 11.7.3. Spain Central Nervous System Drugs Market, 2016, By Segment; Analgesics; Anti-Parkinson Drugs; Anaesthetics; Anti-Epileptics; Other CNS Drugs; 11.7.4. Spain Central Nervous System Drugs Percentage Of GDP, 2012 - 2020; 11.7.5. Spain Per Capita Average Central Nervous System Drugs Expenditure, 2012 - 2020; 12. Eastern Europe Central Nervous System Drugs Market;
12. Eastern Europe Central Nervous System Drugs Market;
12.1.1. Eastern Europe Central Nervous System Drugs Market Overview; 12.1.2. Eastern Europe Central Nervous System Drugs Historic Market, 2012 - 2016; 12.1.3. Eastern Europe Central Nervous System Drugs Forecast Market, 2016 - 2020; 12.1.4 Eastern Europe Central Nervous System Drugs Market, 2016, By Segment; Analgesics; Anti-Parkinson Drugs; Anaesthetics; Anti-Epileptics; Other CNS Drugs; 12.2. Eastern Europe Central Nervous System Drugs Market: Country Analysis; 12.3. Russia Central Nervous System Drugs Market; 12.3.1. Russia Central Nervous System Drugs Historic Market, 2012 - 2016; 12.3.2. Russia Central Nervous System Drugs Forecast Market, 2016 - 2020; 12.3.3. Russia Central Nervous System Drugs Market, 2016, By Segment; Analgesics; Anti-Parkinson Drugs; Anaesthetics; Anti-Epileptics; Other CNS Drugs; 12.3.4. Russia Central Nervous System Drugs Percentage Of GDP, 2012 - 2020; 12.3.5. Russia Per Capita Average Central Nervous System Drugs Expenditure, 2012 - 2020;
13. North America Central Nervous System Drugs Market;
13.1.1. North America Central Nervous System Drugs Market Overview; 13.1.2. North America Central Nervous System Drugs Historic Market, 2012 - 2016; 13.1.3. North America Central Nervous System Drugs Forecast Market, 2016 - 2020; 13.1.4. North America Central Nervous System Drugs Market, 2016, By Segment; Analgesics; Anti-Parkinson Drugs; Anaesthetics; Anti-Epileptics; Other CNS Drugs; 13.2. North America Central Nervous System Drugs Market: Country Analysis; 13.3. USA Central Nervous System Drugs Market; 13.3.1. USA Central Nervous System Drugs Historic Market, 2012 - 2016; 13.3.2. USA Central Nervous System Drugs Forecast Market, 2016 - 2020; 13.3.3 USA Central Nervous System Drugs Market, 2016, By Segment; Analgesics; Anti-Parkinson Drugs; Anaesthetics; Anti-Epileptics; Other CNS Drugs; 13.3.4. USA Central Nervous System Drugs Percentage Of GDP, 2012 - 2020; 13.3.5. USA Per Capita Average Central Nervous System Drugs Expenditure, 2012 - 2020;
14. South America Central Nervous System Drugs Market;
14.1.1. South America Central Nervous System Drugs Market Overview; 14.1.2. South America Central Nervous System Drugs Historic Market, 2012 - 2016; 14.1.3. South America Central Nervous System Drugs Forecast Market, 2016 - 2020; 14.1.4. South America Central Nervous System Drugs Market, 2016, By Segment; Analgesics; Anti-Parkinson Drugs; Anaesthetics; Anti-Epileptics; Other CNS Drugs; 14.2. South America Central Nervous System Drugs Market: Country Analysis; 14.3. Brazil Central Nervous System Drugs Market; 14.3.1. Brazil Central Nervous System Drugs Historic Market, 2012 - 2016; 14.3.2. Brazil Central Nervous System Drugs Forecast Market, 2016 - 2020; 14.3.3. Brazil Central Nervous System Drugs Market, 2016, By Segment; Analgesics; Anti-Parkinson Drugs; Anaesthetics; Anti-Epileptics; Other CNS Drugs; 14.3.4. Brazil Central Nervous System Drugs Percentage Of GDP, 2012 - 2020; 14.3.5. Brazil Per Capita Average Central Nervous System Drugs Expenditure, 2012 - 2020;
15. Middle East Central Nervous System Drugs Market;
15.1.1. Middle East Central Nervous System Drugs Market Overview; 15.1.2. Middle East Central Nervous System Drugs Historic Market, 2012 - 2016; 15.1.3. Middle East Central Nervous System Drugs Forecast Market, 2016 - 2020; 15.1.4. Middle East Central Nervous System Drugs Market, 2016, By Segment; Analgesics; Anti-Parkinson Drugs; Anaesthetics; Anti-Epileptics; Other CNS Drugs;
16. Africa Central Nervous System Drugs Market;
16.1.1. Africa Central Nervous System Drugs Market Overview; 16.1.2. Africa Central Nervous System Drugs Historic Market, 2012 - 2016; 16.1.3. Africa Central Nervous System Drugs Forecast Market, 2016 - 2020; 16.1.4. Africa Central Nervous System Drugs Market, 2016, By Segment; Analgesics; Anti-Parkinson Drugs; Anaesthetics; Anti-Epileptics;
17. Central Nervous System Drugs Market Competitive Landscape;
17.1. Company Profiles; 17.2. Pfizer Inc.; 17.2.1. Overview; 17.2.2. Products And Services; 17.2.3. Strategy; 17.2.4. Financial Performance; 17.3. Biogen Idec; 17.3.1. Overview; 17.3.2. Products And Services; 17.3.3. Strategy; 17.3.4. Financial Performance; 17.4. Novartis Ag; 17.4.1. Overview; 17.4.2. Products And Services; 17.4.3. Strategy; 17.4.4. Financial Performance; 17.5. Otsuka; 17.5.1. Overview; 17.5.2. Products And Services; 17.5.3. Strategy; 17.5.4. Financial Performance; 17.6. Teva Pharmaceuticals; 17.6.1. Overview; 17.6.2. Products And Services; 17.6.3. Strategy; 17.6.4. Financial Performance;
18. Key Mergers And Acquisitions In The Central Nervous System Drugs Market;
19. Market Background: Pharmaceutical Drugs Market;
19.1.1. Pharmaceutical Drugs Market Characteristics; 19.1.2. Pharmaceutical Drugs Market Historic Growth; 19.1.2.1. Drivers Of The Market; 19.1.2.2. Restraints Of The Market; 19.1.3. Pharmaceutical Drugs Market Forecast Growth; 19.1.3.1. Drivers Of The Market; 19.1.3.2. Restraints Of The Market; 19.1.4. Pharmaceutical Drugs Trends And Strategies; 19.2. Pharmaceutical Drugs Market Regional And Country Analysis; 19.2.1. Global Pharmaceutical Drugs Market, 2016, By Region; 19.2.2. Global Pharmaceutical Drugs Market, 2012 - 2020, Historic And Forecast, By Region; 19.2.3. Pharmaceutical Drugs Market, 2016, By Country; 19.2.4. Pharmaceutical Drugs Market, 2012 - 2020, Historic And Forecast, By Country; 19.2.5. Global Pharmaceutical Drugs Market, Growth And Market Share Comparison, By Segment; 19.2.6. Global Pharmaceutical Drugs Market, Growth And Market Share Comparison, By Country And Segment; 19.3. Global Pharmaceutical Drugs Market Comparison With Macro Economic Factors; 19.3.1. Pharmaceutical Drugs Market Size, Percentage Of GDP, Global; 19.3.2. Per Capita Average Pharmaceutical Drugs Expenditure, Global; 19.4. Pharmaceutical Drugs Market Comparison With Macro Economic Factors Across Countries; 19.4.1. Pharmaceutical Drugs Market Size, Percentage Of GDP, By Country; 19.4.2. Per Capita Average Pharmaceutical Drugs Expenditure, By Country; 19.5. Key Mergers And Acquisitions In The Pharmaceutical Drugs Market;
20. Pharmaceuticals Industry Financial Margins;
21. Appendix;
21.1. NAICS Definitions Of Industry Covered In This Report; 21.2. Abbreviations; 21.3. Currencies; 21.4. Research Inquiries; 21.5. The Business Research Company; 21.6. Copyright And Disclaimer
